NASDAQ: LQDALiquidia Corp Stock
$28.58+0.90 (+3.25%)
Updated Sep 2, 2025
LQDA Price
$28.58
Fair Value Price
-$23.67
Market Cap
$2.46B
52 Week Low
$8.75
52 Week High
$29.28
P/E
-16.81x
P/B
161.99x
P/S
55.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.32M
Earnings
-$141.47M
Gross Margin
69.3%
Operating Margin
-640.62%
Profit Margin
-732.2%
Debt to Equity
15.95
Operating Cash Flow
-$116M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LQDA Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LQDA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LQDA
Ranked#173 of 482
Ranked#173 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.84 | A | |
| $38.46 | A | |
| $11.68 | A |
Be the first to know about important LQDA news, forecast changes, insider trades & much more!
LQDA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LQDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LQDA ($28.58) is overvalued by 220.72% relative to our estimate of its Fair Value price of -$23.67 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LQDA ($28.58) is not significantly undervalued (220.72%) relative to our estimate of its Fair Value price of -$23.67 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LQDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LQDA due diligence checks available for Premium users.
Valuation
LQDA fair value
Fair Value of LQDA stock based on Discounted Cash Flow (DCF)
Price
$28.58
Fair Value
-$23.67
Undervalued by
220.72%
LQDA ($28.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LQDA ($28.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LQDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LQDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.81x
Industry
-112.37x
Market
34.73x
LQDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
161.99x
Industry
4.65x
LQDA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LQDA's financial health
Profit margin
Revenue
$8.8M
Net Income
-$41.6M
Profit Margin
-470.5%
LQDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LQDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$257.4M
Liabilities
$242.2M
Debt to equity
15.95
LQDA's short-term assets ($195.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LQDA's short-term assets ($195.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LQDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LQDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.5M
Investing
-$1.1M
Financing
$47.7M
LQDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LQDA vs Biotech Stocks
Liquidia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.